Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

Study Identifier
MAF/AGN/OPH/RET/012
CT.gov Identifier
NCT01566526
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Macular Edema
    • Study Drug
  • dexamethasone intravitreal implant 0.7 mg
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Macular oedema in at least one eye due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) * Received at least two OZURDEX® injections in the study eye as part of the Belgium Medical Needs Program
    Exclusion Criteria:
    * None

    Protocol Summary

    The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX® as part of the Belgium Medical Needs Program.

    Study Locations

    Location
    Status
    Location
    Antwerp, Belgium
    Status
    Not applicable